Linlin Yin

Mr. Linlin Yin


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
LYLinlin Yin
Linlin Yin
HYHaihao Yan
Haihao Yan
KCKangdi Chen
Kangdi Chen
ZJZuhong Ji
Zuhong Ji
XZXiuhua Zhang
Xiuhua Zhang
BZBin Zhang
Bin Zhang
Previous observational case-control studies have shown significant controversy over the impact of dietary intake-related circulating antioxidants on the risk of digestive system tumors. We conducted a two-sample Mendelian randomized (MR) analysis to determine whether there was a significant causal relationship between increased levels of circulating antioxidants and digestive system tumors. Our circulating antioxidants (vitamin C, carotenoids, vitamin A, and vitamin E) were derived from absolute circulating antioxidants and circulating antioxidant metabolites, and their corresponding instrumental variables were screened from published studies. The digestive system tumors we studied included colorectal, gastric, pancreatic, liver, and esophageal cancer, and the corresponding summary GAWS (genome-wide association study) data were obtained from the UK Biobank database. We first evaluated the causal relationship between each tumor and circulating antioxidants and then used meta-analysis to summarize the results of MR analysis of different tumors. No significant associations were noted for genetically predicted circulating antioxidants and higher risk of digestive system tumors in our study. The pooled ORs (odds ratio) are 0.72 (95% CI: 0.46–1.11; β-carotene), 0.93 (95% CI: 0.81–1.08; lycopene), 2.12 (95% CI: 0.31–14.66; retinol), and 0.99 (95% CI: 0.96–1.02; ascorbate) for absolute circulating antioxidants; for circulating antioxidant metabolites, the pooled ORs for digestive system tumors risk per unit increase of antioxidants were 1.29 (95% CI: 0.39–4.28; α-tocopherol), 1.72 (95% CI: 0.85–3.49; γ-tocopherol), 1.05 (95% CI: 0.96–1.14; retinol), and 1.21 (95% CI: 0.97–1.51; ascorbate), respectively. Our study suggested that increased levels of dietary-derived circulating antioxidants did not reduce the risk of digestive system tumors.

31 October 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
HYHaihao Yan
Haihao Yan
XJXiao Jin
Xiao Jin
LYLinlin Yin
Linlin Yin
CZChangjun Zhu
Changjun Zhu
GFGanzhu Feng
Ganzhu Feng
Previous observational studies have suggested that the effect of diet-derived circulating micronutrient concentrations on lung cancer (LC) risk is controversial. We conducted a two-sample Mendelian randomization (MR) analysis to investigate the causal relationship between circulating micronutrient concentrations and the overall risk of LC and three LC subtypes (namely lung adenocarcinoma (LA), squamous cell lung cancer (SqCLC), and small cell lung cancer (SCLC)). The instrumental variables (IVs) of 11 micronutrients (beta-carotene, calcium, copper, folate, lycopene, magnesium, phosphorus, retinol, selenium, zinc, and vitamin B6) were screened from the published genome-wide association studies (GWAS). Summary statistics related to LC and its subtypes came from the largest meta-analysis, including 29,266 cases and 56,450 controls. Inverse-variance weighted (IVW) method is used as the main MR analysis, and the sensitivity analysis is carried out to ensure the MR assumptions. This MR study found suggestive evidence that genetically predicted 6 circulating micronutrient concentrations was correlated with the risk of overall LC (odds ratio (OR): 1.394, 95% confidence interval (CI): 1.041–1.868, p = 0.026, phosphorus), LA (OR: 0.794, 95% CI: 0.634–0.995, p = 0.045, beta-carotene; OR: 0.687, 95%CI: 0.494–0.957, p = 0.026, calcium), SqCLC (OR: 0.354, 95% CI: 0.145–0.865, p = 0.023, retinol), and SCLC (OR: 1.267, 95% CI: 1.040–1.543, p = 0.019, copper; OR: 0.801, 95% CI: 0.679–0.944, p = 0.008, zinc). We found no evidence that other micronutrients are associated with the risk of overall LC or its subtypes. Our study suggested that the increase in circulating beta-carotene, calcium, retinol, and zinc concentration may reduce the risk of LC; the increase in circulating copper and phosphorus concentration may be related to the increased risk of LC. In the future, larger replication samples of LC genetic data and larger micronutrient-related GWAS will be needed to verify our findings.

10 September 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
LYLinlin Yin
Linlin Yin
YZYue Zhu
Yue Zhu
FKFang Kong
Fang Kong
HTHongfei Tu
Hongfei Tu
BZBin Zhang
Bin Zhang
The existing studies indicate that the lipidome may be associated with inflammatory bowel disease (IBD). However, most of the results of previous studies are based on epidemiological or observational studies. Meanwhile, the causal association between different lipids and inflammatory bowel diseases, as well as whether inflammatory proteins act as mediators, remains unclear. We employed Mendelian randomized (MR) analysis to investigate the causal relationship between lipidome and IBD (ulcerative colitis and Crohn's disease). We mainly used the IVW method for MR analysis and further evaluated heterogeneity and pleiotropy. Additionally, we explored whether circulating inflammatory proteins play a mediating role in the pathway from the lipidome to IBD. In our MR study, we identified causal relationships between four classes of lipids (sterol ester, phosphatidylcholine, sphingomyelin, and phosphatidylethanolamine) and IBD. The risk of IBD is positively associated with the levels of 6 inflammatory proteins (CCL19, CCL4, CD5, CD6, IL‐10α, and TNFSF12). In the mediation analysis, we identified two circulating inflammatory proteins (CD6, CCL4) that play a mediating role between the lipidome and IBD. Plasma lipidome was causally associated with IBD, and circulating inflammatory proteins serve as mediating factors in the pathway from lipidome to IBD.

25 August 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
LYLinlin Yin
Linlin Yin
HTHongfei Tu
Hongfei Tu
YZYue Zhu
Yue Zhu
JQJingjing Qian
Jingjing Qian
YYYang Yang
Yang Yang
BZBin Zhang
Bin Zhang
Helicobacter pylori (H. pylori) infection in the stomach can lead to alterations in the gut microbiota. However, the association between H. pylori infection and Clostridioides difficile infection (CDI) remains unclear. We conducted a retrospective cross-sectional study to evaluate the association between H. pylori infection and CDI. We included patients hospitalized for diarrhea at our center between 2019 and 2024 who underwent both H. pylori and CDI testing during their hospital stay. H. pylori infection was diagnosed using either the carbon-13 urea breath test or the rapid urease test. CDI was diagnosed using a two-step testing algorithm. Patients were categorized into H. pylori-positive and -negative groups. We compared the prevalence of CDI between groups and assessed the association using logistic regression. To adjust for potential confounders, propensity score matching (PSM) was performed, followed by further analysis. We included 1,624 patients: 732 H. pylori-positive and 892 H. pylori-negative. The prevalence of CDI was significantly higher in the H. pylori-positive group (13.7%, 95% CI: 11.2%-16.2%) compared to the H. pylori-negative group (9.0%, 95% CI: 7.1%-10.8%) (P = 0.003). Univariate logistic regression showed that H. pylori infection was associated with CDI (OR: 1.606, 95% CI: 1.176–2.194; P = 0.003). Multivariate analysis also suggested that H. pylori infection was independently associated with CDI (OR: 1.817, 95% CI: 1.320–2.501; P < 0.001). This association remained significant after PSM. Our findings suggest that current H. pylori infection may be associated with Clostridioides difficile infection.

26 December 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
LYLinlin Yin
Linlin Yin
BZBin Zhang
Bin Zhang
The effect of aspirin on liver fibrosis is still controversial. To further explore the effect of aspirin on liver fibrosis in metabolic dysfunction‐associated steatotic liver disease (MASLD), we conducted this study. We applied NHANES database data to evaluate the degree of liver fibrosis through fibroscan and explored the impact of aspirin on liver fibrosis in patients with MASLD from a cross‐sectional study based on the American population. Considering the shortcomings of cross‐sectional studies, we also applied Mendelian randomization (MR) analysis, a novel research method, to evaluate the potential causal relationship of aspirin on liver fibrosis and cirrhosis from a genetic perspective. In a cross‐sectional study of the NHANES database, we did not find that aspirin significantly improved the prognosis of liver fibrosis in MASLD patients after adjusting for possible confounding biases by multivariable logistic regression analysis. Similarly, in univariate and multivariate MR analyses, we did not observe a potential causal relationship between aspirin and liver fibrosis or cirrhosis. Our study did not find that aspirin significantly reduced the risk of liver fibrosis in MASLD patients based on cross‐sectional studies of the American population and genetic associations by MR analysis.

20 May 2025 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
LYLinlin Yin
Linlin Yin
CDChenliang Ding
Chenliang Ding
YLYi Li
Yi Li
LCLei Cao
Lei Cao
HTHongfei Tu
Hongfei Tu
JGJianfeng Gong
Jianfeng Gong
INTRODUCTION: Anastomotic ulcers are common after ileocolonic resection in patients with Crohn's disease (CD). However, the endoscopic prognosis of isolated anastomotic lesions after treatment adjustment remains unclear. METHODS: We retrospectively included CD patients with anastomotic lesions who were referred to our center for ileocolonoscopy between 2020 and 2024. We conducted an initial evaluation of the impact of treatment adjustment on the endoscopic prognosis of anastomotic lesions. In addition, we analyzed the association between different adjustment strategies and endoscopic outcome. RESULTS: In total, 199 eligible CD patients with anastomotic lesions were included in our study. Treatment adjustment promoted mucosal healing (multivariable Cox hazard ratio [HR]: 2.376, 1.400–4.032, P = 0.001) and endoscopic improvement (multivariable Cox HR: 2.373, 1.596–3.530, P < 0.001). We also found that the endoscopic ulcer improvement of biologics to biologics switching was superior to that of nontreatment adjustment (Cox HR: 2.055, 1.212–3.482, P = 0.007). Cox regression analyses further confirmed that nonbiologics to biologics switching was associated with better endoscopic mucosal healing (Cox HR: 2.751, 1.494–5.063, P = 0.001) and ulcer improvement (Cox HR: 2.154, 1.322–3.509, P = 0.002). Regarding patients with insufficient trough levels of biologics, biologic optimization significantly improved endoscopic mucosal healing (Cox HR: 2.854, 1.345–6.053, P = 0.006) and endoscopic ulcer improvement (Cox HR: 2.344, 1.288–4.265, P = 0.005). DISCUSSION: Treatment adjustment contributed to the improvement of endoscopic prognosis in anastomotic lesions patients. Different adjustment strategies (biologics to biologics switching, nonbiologics to biologics switching, biologic optimization) similarly resulted in better endoscopic outcome.